Pharmacogenomics and Pharmacoproteomics Studies of Phosphodiesterase-5 (PDE5) Inhibitors and Paclitaxel Albumin-Stabilized Nanoparticles as Sandwiched Anti-Cancer Nano Drugs between Two DNA/RNA Molecules of Human Cancer Cells

One of the most important goals in the medicine, pharmacology, pharmaceutical, physiological, clinical, biological, medical and medicinal sciences, biochemistry, pharmacogenomics and pharmacoproteomics of anti-cancer Nano drugs such as phosphodiesterase-5 (PDE5) inhibitors and paclitaxel albuminstabilized nanoparticles is the treatment. The present methods and techniques of Nano-structuring anti-cancer Nano drugs, especially phosphodiesterase-5 (PDE5) inhibitors and paclitaxel albuminstabilized nanoparticles, are expected to reach their limitations in the next decades. The smallest anti-cancer Nano drugs are of about five nanometers wide and hundreds of millions of them maybe integrated on a single molecule. Below this size the controlled doping becomes more and more difficult. The next important step in the treatment might be done by reducing the anti-cancer Nano drugs such as phosphodiesterase-5 (PDE5) inhibitors and paclitaxel albuminstabilized nanoparticles to the scale of DNA/RNA molecules of human cancer cells (Figures 1 and 2). This new filed of medicine, pharmacology, pharmaceutical, physiological, clinical, biological, medical and medicinal sciences, biochemistry, pharmacogenomics and pharmacoproteomics is called pharmachemotherapy. Recently, several researchers have measured electron transport in single or small groups of bioorganic molecules such as DNA/RNA of human cancer cells connected to metal such as Cadmium or Ruthenium (Figure 3) [1-29].